Bioness to Sponsor Educational Session on Peripheral Nerve Stimulation at 2019 North American Neuromodulation Society’s Annual Meeting

Clinical experts will share insights on present and future applications of neuromodulation technology

Valencia, CA (January 17, 2019)—Bioness, Inc., announced the company is sponsoring an educational lunch session at the 2019 North American Neuromodulation Society’s Annual Meeting in Las Vegas, Nevada. Bioness is the leading provider of state-of-the-art, clinically supported rehabilitation and pain management medical devices. The lunch session is titled “PNS Insights: Past, Present, and Future” and will be held on January 19, 2019 at 12:30pm. The presentation will feature information from clinical experts on innovations in peripheral nerve stimulation (PNS) in addition to current and future applications of PNS technology for patients suffering with chronic pain.

PNS technology is rapidly growing amongst clinicians and patients due to its proven effectiveness at reducing pain and dependence on opioids for the 50 million Americans currently living with chronic pain. Bioness developed the StimRouter® to help patients with chronic pain due to stroke, accident, or other injury. StimRouter is the first FDA cleared, longterm, minimally invasive peripheral nerve stimulator indicated to treat chronic pain of a peripheral nerve origin. During the session implanting physicians of the StimRouter, Dr. David Spinner, DO, Dr. Michael Gofeld, MD, PhD, FRCPC, and Dr. Einar Ottestad, MD, will discuss how PNS technology can provide significant relief to patients with peripheral nerve pain.

“In light of the current opioid crisis, better access to non-opioid treatments like PNS is vitally important. Physicians should be aware of the benefits of neuromodulation technology and how they can offer this type of innovation to patients with chronic pain,” said Todd Cushman, President and CEO at Bioness.

NANS attendees are invited to Augustus Conference Rooms 5 and 6 at Caesar’s Palace to attend PNS Insights: Past, Present, and Future at 12:30pm where lunch will be served.

For more information on the educational lunch session, stop by Bioness’ booth #316 at NANS or for more information about the StimRouter, visit

About StimRouter® Neuromodulation System

StimRouter is approved by the FDA to treat chronic pain of peripheral nerve origin, excluding pain in the craniofacial region. StimRouter is a minimally invasive neuromodulation medical device consisting of a thin, implanted lead with conductive electrode, external pulse transmitter (EPT), and hand-held wireless patient programmer. Electrical signals are transmitted transdermally from the EPT through the electrode, down the lead to the target nerve.

StimRouter is programmed at the direction of the physician to meet patient requirements but is controlled by the patient to address the patients’ specific, changing pain management needs

About Bioness Inc.

Bioness is the leading provider of innovative technologies helping people regain mobility and independence. Bioness solutions include implantable and external neuromodulation systems, robotic systems, and software based therapy programs providing functional and therapeutic benefits for individuals affected by pain, central nervous system disorders, and orthopedic injuries. Currently, Bioness offers six medical devices within its commercial portfolio which are distributed and sold on five continents and in over 25 countries worldwide. Our technologies have been implemented in the most prestigious and well-respected institutions around the globe with approximately 90% of the top rehabilitation hospitals in the United States currently using one or more Bioness solutions. Bioness has a singular focus on aiding large, underserved customer groups with innovative, evidence-based solutions and we will continue to develop and make commercially available new products that address the growing and changing needs of our customers. Individual results vary. Consult with a qualified physician to determine if this product is right for you. Contraindications, adverse reactions and precautions are available online at

Media Relations Contact Information
Next Step Communications
[email protected]